Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01849055 · ClinicalTrials.gov registry record · Phase 1
A Multiple Dose Study of LY3023703 in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT01849055 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 48 participants.
The verdict
NCT01849055, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This is a study of LY3023703 in healthy participants. The purposes of this study are to look at safety, how well the study drug is tolerated, how much of the study drug gets into the blood stream and how long it takes the body to remove the study drug. The effects of LY3023703 on blood pressure after 28 days of dosing will be studied. Information about any side effects that occur will be collected. The study is expected to last 21 weeks.
Interventions
- DRUG Placebo
- DRUG Celecoxib
- DRUG LY3023703
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2013-05 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01849055
The ClinicalTrials.gov registry entry for NCT01849055 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01849055 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01849055 about?
NCT01849055 is a clinical study titled "A Multiple Dose Study of LY3023703 in Healthy Participants". This is a study of LY3023703 in healthy participants. The purposes of this study are to look at safety, how well the study drug is tolerated, how much of the study drug gets into the blood stream and how long it takes the body to remove the study drug. The effects of LY3023703 on blood pressure afte...
What is the current status of trial NCT01849055?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2013-05. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01849055?
The interventions under investigation include: Placebo (DRUG), Celecoxib (DRUG), LY3023703 (DRUG).
Who is sponsoring clinical trial NCT01849055?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.